0001637715 false 0001637715 2021-08-11 2021-08-11

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported):

August 11, 2021

Reneo Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

​

​ | ​ | ​ | ​ | ​
Delaware |  | 001-40315 |  | 47-2309515
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (I.R.S. Employer Identification No.)

​

​

​ ​ | ​
18575 Jamboree Road, Suite 275-S, Irvine, California | 92612
(Address of principal executive offices) | (Zip Code)

​

Registrant’s telephone number, including area code: (858) 283-0280

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.0001 per share | RPHM | The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

​

Emerging growth company ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 7.01Regulation FD Disclosure.

On August 11, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) updated its corporate slide presentation for use in meetings with investors, analysts and others. The presentation is available through the Company’s website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

99 | ​ | ​
Exhibit No. |  | Description
99.1 | ​ | Corporate Slide Presentation, dated August 11, 2021.
104 | ​ | Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​ | ​ | ​ | ​
​ | Reneo Pharmaceuticals, Inc.
​ | ​
Date: August 11, 2021 | By: | ​ | /s/ Gregory J. Flesher
​ | ​ | ​ | Gregory J. Flesher
​ | ​ | ​ | Chief Executive Officer

​

​

​

​

​